For instance, it was reported that only one third of flavonoid trials for Alzheimer’s disease involved standardized biomarkers, such as p-Tau protein or cerebrospinal fluid Aβ42 [168]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.